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Highlights 
 Substantial disease burden is associated with MRSA resistance in the Asia Pacific region. 
 Study design explained the variance in the reported MRSA resistance. 
 No secular change in MRSA resistance patterns in the Asia Pacific region. 
 Variation in MRSA resistance could not be explained by testing methods. 
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ABSTRACT 
Objective We aimed to review published literature on methicillin resistant S. aureus (MRSA) in 
the Asia Pacific Region to document MRSA prevalence in the Region and examine the impact of 
variability in study design on the reported data of MRSA prevalence. 
Methods We included studies that reported MRSA prevalence between 2000 and 2016 and 
excluded studies if they did not contain complete information on antibiotic susceptibility testing 
(AST) methods. Our primary outcomes were the proportion of MRSA isolates among S. aureus 
isolates (resistance proportion) or among individual samples (prevalence). 
Findings We included 229 studies in 19 countries/territories in this study. There was substantial 
heterogeneity in both outcomes (resistance proportion: I2 = 99·6%, prevalence: I2 = 99·8%), 
precluding pooled averages, and meta-regression analyses revealed that these variations were 
explained by country income status and participant characteristics but not methodological 
differences in AST. We also found no significant secular changes in MRSA prevalence or 
resistance proportions in the Asia Pacific. 
Conclusion The resistance proportions and prevalence of MRSA infections in the Asia Pacific is 
comparable to those reported in other regions with no significant secular changes in the past decade. 
Country income status and the characteristics of the sample population explained more variations 
in the reported resistance proportions and prevalence of MRSA than methodological differences 
in AST across locations in the Region. 
 
Keywords: 
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1. INTRODUCTION 
Antimicrobial resistance (AMR) is a major public health concern globally and methicillin resistant 
Staphylococcus aureus (MRSA) is one of the most important pathogens worldwide, accounting 
for over 80,000 severe infections in the United States alone in 2011 and more than half of hospital-
related Staphylococcus aureus (S. aureus) infections in most Asian countries.1, 2 In particular, the 
spread of MRSA infections from healthcare settings to various community settings over recent 
decades has raised considerable concern.3 While the prevalence of methicillin resistance among 
invasive S. aureus infections is reported to be on the decline in Europe and the US,4, 5 resistance 
remains common in Asia, where self-medication with antibiotics is common.6  
 
The Asia Pacific region is the most populous region in the world, with one-third of the world’s 
population.7 With rapid urbanization, a significant proportion of people in this region live in high-
density cities, which increases the risk of the development and spread of antibiotic resistance.8 
Since the 1980’s, methicillin resistance detection in S. aureus in healthcare settings within Asia 
has increased significantly, with regional detection proportions ranging from 26% to 73% in 2011.9 
This poses significant health burden on healthcare systems in the region, especially in resource 
limited countries where S. aureus infection frequently presents as severe or invasive diseases.10 
The overall mortality from S. aureus blood infection was 48% in a study conducted in northeast 
Thailand.11 which is almost double the mortality rate reported in a similar study in the United 
States.12 Although decreasing proportions of healthcare-associated MRSA (HA-MRSA) have been 
reported in Taiwan and Japan since 2000, community-associated MRSA (CA-MRSA) infections 
are increasingly detected in the region.13 As MRSA remains an important cause of nosocomial and 
community infections in the region, and antibiotic susceptibility patterns may differ between HA-
AC
CE
PT
ED
 M
AN
US
CR
IPT
4 
MRSA and CA-MRSA strains, knowledge about their respective distributions in the population is 
important for the treatment and management of MRSA infections.14 Besides infections, there have 
also been increasing reports of MRSA carriage in various population groups in the region, 
including in young children and adults.6 While MRSA carriers do not experience clinical 
symptoms as a result of carriage, they may be at higher risk of MRSA infection especially in the 
event of hospitalization or major invasive procedures.15 Nevertheless, epidemiological trends in 
methicillin-resistance among S. aureus isolates are difficult to determine in the absence of 
established and standardized common surveillance protocols in the region.16  
 
Variations in published measures of methicillin-resistance in S. aureus isolates also complicate the 
interpretability of MRSA detection data. Typically, levels of methicillin resistance in S. aureus 
within a selected population are measured using isolate-based screening, in which resistance is 
measured as a proportion of MRSA detected among S. aureus that are successfully isolated from 
individual samples. This strategy is used by most established AMR surveillance networks, 
including the European Antimicrobial Resistance Surveillance Network (EARS-Net) and the 
WHO Global Antimicrobial Resistance Surveillance System (GLASS).17, 18 However, as more 
laboratory methods (e.g. screening agars) were made available for the detection of MRSA directly 
from clinical specimens, some studies today report methicillin resistance levels using a sample-
based approach, where resistance is measured as a proportion of MRSA detected from all clinical 
samples, including samples testing negative for S. aureus. While the isolate-based and the sample-
based approaches measure methicillin resistance in S. aureus in different subsets of the population, 
MRSA resistance quantified with the two approaches is often compared with one another and 
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described with non-standardized terms such as “resistance”, “resistance rates”, “incidence” and 
“prevalence”.19, 20  
 
Therefore, in this systematic review, we sought to document methicillin resistance in S. aureus 
based on published literature in the Asia Pacific region. We paid particular attention to the 
surveillance metrics used, and examined the impact of variability in study participants, source of 
infection, and laboratory methods on MRSA prevalence.  
 
2. METHODS 
2.1 Search strategy 
This systematic review was conducted in accordance with the PRISMA-P 2015 guidelines.21 We 
systematically searched literature published through 5 December 2017 on methicillin resistance in 
S. aureus reported in 41 countries and regions in the Asia Pacific Region using the bibliographic 
databases PubMed and Embase (Appendix). Search results were catalogued using bibliographic 
software (Endnote version X7, Clarivate Analytics), and a database was generated to manage 
article screening and evaluation. In this review, the Asia Pacific Region refers to countries and 
regions that comprise Eastern Asia, South-Eastern Asia, and Oceania according to the definitions 
provided by the United Nations Statistics Division.  
 
2.2 Study selection 
Three reviewers (WWL, JW and KN) independently screened titles, abstracts, and full texts of 
articles. Disagreements between the reviewers were resolved by the decision of a fourth author 
(PW). Studies were included in this review if they were original studies that met all of the following 
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conditions: (1) assessed methicillin resistance in S. aureus isolated from clinical specimens 
collected from populations in the Asia Pacific Region, (2) assessed methicillin resistance in S. 
aureus isolates between 2000 and 2016, (3) expressed antibiotic resistance in proportions (%) of 
resistant organisms, (4) were written in English, and (5) had a full text accessible to the review 
team (Appendix). Studies were excluded if they were (1) randomized controlled trials, reviews, 
case studies, opinions, or multiple publications of the same dataset (only one publication per 
dataset was included), (2) studies that did not state laboratory methods or standards for 
susceptibility testing, (3) studies that did not specify individual drug or antibiotic names used for 
susceptibility testing, (4) studies that included data before year 2000 that could not be 
disaggregated from later data, and (5) studies in which the study period was not clearly defined. 
The third exclusion criteria was not applicable to studies that assessed methicillin resistance in S. 
aureus through automated AST methods or molecular and screening methods such as resistance 
gene identification with polymerase chain reaction (PCR) and biochemical MRSA screening tests. 
 
2.3 Data extraction 
We extracted the following data from each included study using a standardized form: author and 
year of publication, country, type of study, study period, sample population, participant age range, 
setting, source of infection, sampling site, sample size, laboratory methods, laboratory standards 
for antimicrobial susceptibility testing, whether unique patient isolates were used to avoid 
duplication of samples, and proportion of S. aureus resistant to methicillin, cefoxitin, oxacillin, or 
flucloxacillin out of total samples tested (prevalence) or S. aureus isolates tested (resistance 
proportion) (Appendix). 
 
AC
CE
PT
ED
 M
AN
US
CR
IPT
7 
2.4 Data analysis 
We first described the overall search results (i.e. resistance proportions and prevalence of MRSA) 
for all countries with available data. In this review, we define “MRSA prevalence” as the 
proportion of MRSA among all tested samples, and “MRSA resistance proportion” as the 
proportion of MRSA among all S. aureus isolates. Articles that reported resistance proportions and 
prevalence for different years, sampled populations, or source of infections had individual entries 
recorded for each year, population subgroup (e.g. inpatients and outpatients recorded separately), 
and source of infection (e.g. hospital-associated infections are recorded separately from 
community-associated infections) or carriage. MRSA prevalence and resistance proportions were 
double arcsine-transformed22 and combined using a Restricted Maximum-Likelihood (REML)-
based random-effects model.23, 24 Statistical heterogeneity for MRSA prevalence and resistance 
proportion were assessed with the I2 statistic, the value of which indicates the proportion of 
variation in reported estimates across studies that can be attributed to heterogeneity between these 
studies rather than chance.25, 26 Meta-regression analyses were conducted using multivariable 
mixed-effect models for studies that reported MRSA prevalence and resistance proportions, and 
reports on MRSA carriage were analyzed separately from MRSA infections. Covariates of interest 
included country gross national income (GNI) per capita, study year, participant age group, AST 
method, sampling site, and the use of unique patient isolates to avoid duplication of samples. The 
influence of sample population on the prevalence and resistance proportions of MRSA carriage, 
and source of infection on the prevalence and resistance proportions of MRSA infections were 
also investigated. All data were visualized and analyzed in R version 3.4.1 (R Development Core 
Team, Vienna, Austria) with the metafor package,27 as well as the Quantum GIS Geographic 
Information System version 2.18.7 (QGIS, Open Source Geospatial Foundation Project).28 
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3. RESULTS 
3.1 Study characteristics 
From the 9546 articles identified through our search on the PubMed and Embase databases, 7994 
abstracts were screened, 749 full text articles were assessed, and 229 articles that reported MRSA 
prevalence and resistance proportions in 19 of the 41 selected countries/territories in the Asia 
Pacific region between year 2000 and 2016 were included (Figure 1). Most articles were excluded 
because they did not report methicillin resistance (n=123) or the methods and test antibiotics used 
in antibiotic susceptibility tests (n=240). Detailed study characteristics are available in the 
Appendix. Of the 229 included articles, 210 were published on or after year 2007 (Table 1). As 
MRSA prevalence and resistance proportions for different years, sample population, and source of 
infection in the same study were recorded as separate observations, 346 observations or data points 
were included in this review. 
 
There were more reports of methicillin resistance as a proportion of MRSA isolates among S. 
aureus isolates (n=293) than among individual samples (n=216). Most observations were results 
from studies conducted in healthcare settings (n=311), among inpatients (n=146), and in single 
sites (n=209). More than 75% of the observations recorded in this review were reports of MRSA 
infections (n=263) and the remaining observations were of MRSA carriage (n=83). A substantial 
number of studies were conducted in adults (43%) while 33% of the studies included samples or 
isolates from individuals from all ages.  
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Almost half (45%) of included observations used the disk diffusion method for AST, and oxacillin 
was used as the test antibiotic in around two-thirds of these observations. Half of all included 
observations assessed antibiotic resistance of S. aureus isolated from various body sites, and the 
most common sampling sites were the respiratory tract (22%), blood (14%), and skin or wound 
(7%). The types of samples collected from the respiratory tract include sputum, nasal swabs, and 
throat swabs, and samples collected from the skin or wound include pus and swabs taken from 
sites such as the axilla and groin. 
 
3.2 Estimates of MRSA prevalence and resistance proportions 
The most observations (prevalence and resistance proportions) between year 2000 and 2016 were 
reported from mainland China (n=74), Taiwan (n=64), Australia (n=62), South Korea (n=30), 
Japan (n=30), Hong Kong (n=20), and Thailand (n=15). 12 locations reported fewer than 10 
observations each (Figure 2). Overall, the prevalence of MRSA infections in the 19 locations 
ranged from 0% to 73% between year 2000 and 2016 (Figure 3). The resistance proportions of 
MRSA infections ranged from 0% to 98·4% for the same period. The prevalence and resistance 
proportions of MRSA carriage ranged from 0% to 39·1% and 0% to 88·9% respectively. However, 
these proportions vary considerably between locations (Table 2). 
 
3.3 Factors that influence prevalence and resistance proportions of MRSA carriage and 
infections 
A high degree of statistical heterogeneity was indicated in estimates of the MRSA prevalence and 
resistance proportion (prevalence: I2 = 99.83%, resistance proportion: I2 = 99.59%) using a 
restricted maximum-likelihood (REML) random-effects model. Meta-regression analyses were 
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conducted to assess the potential association between the reported prevalence and resistance 
proportions of MRSA carriage and infections and study variables (including country grouped by 
income status (GNI per capita), study year, participant age group, AST method, sample population, 
source of infection, sampling site, and the use of unique patient isolates to avoid duplication of 
samples). Factors showing a statistically significant association with MRSA carriage or infections 
are presented in Tables 3 and 4, including country grouped by income status (GNI per capita), 
study year, and sample population groups.  
 
Meta-regression results show non-significant (p>0.05) temporal increases in the prevalence and 
resistance proportions of MRSA carriage and the resistance proportions of MRSA infections 
during the study period (2000 – 2016). However, temporal increases in prevalence for MRSA 
infections were statistically significant. In studies that reported MRSA carriage, we found 
significantly higher prevalence of MRSA in older adults compared with children (less than 18 
years old), and significantly lower prevalence in outpatients and healthy participants compared 
with inpatients (Figure 4). GNI per capita was associated with increases in the prevalence of 
MRSA carriage and infections. However, this association was not significant for resistance 
proportion of MRSA carriage, and the association was significantly negative in the resistance 
proportion of MRSA infection. In studies that report MRSA infections, there were no statistically 
significant associations between the age group of participants and MRSA prevalence or resistance 
proportions. However, we found lower prevalence of MRSA infections in upper middle and lower 
middle-income countries compared with high income countries. Generally lower prevalence and 
resistance proportions of MRSA infections were reported in community-associated or livestock-
associated infections compared with hospital-associated infections, although no statistically 
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significant association was shown between the prevalence of MRSA infections and the source of 
infections. 
 
4. DISCUSSION 
Methicillin resistance in S. aureus has been documented in the Asia Pacific region since the 1960’s 
shortly after methicillin became available for clinical use. While there has been an increase in 
published studies on methicillin resistance in S. aureus especially after the mid-2000s, there are 
substantial variations in approaches to measure resistance across the studies included in this review. 
As noted in previous narrative reviews, most studies are hospital-based, single-institution studies 
conducted predominantly in better-resourced countries in East and Southeast Asia.6, 13  
 
Although a pooled average MRSA prevalence or resistance proportion could not be reliably 
estimated for the current review due to the substantial statistical heterogeneity across the included 
studies, the range of resistance proportions for MRSA infections and prevalence for MRSA 
carriage recorded in locations where data were available was consistent with previous reports.6, 9 
The range of MRSA infections reported the Asia Pacific region in our study (0% - 98.4%) was 
comparable to resistance proportions reported in Europe (19·7% - 21.5%)18, 29 and the Middle East 
(12·4% - 30%),30 and lower than those reported in the United States (29% - 43.2%)31, 32 and Africa 
(16% - 55%).19 East Asian locations reported the highest resistance proportions (above 40%) in 
the region followed by South-east Asian locations (20% and 30%). MRSA prevalence reported in 
the Asia Pacific region are similar to those reported in other regions and are typically between 1% 
and 25%.33, 34  
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On average, we observed positive but mostly non-significant secular trends in MRSA prevalence 
and resistance proportions for MRSA infections or carriage in the past 16 years even when 
between-country differences and methodological variation such as laboratory methods and 
sampling sites were considered. As there is no consensus or a most appropriate metric to report 
levels of methicillin resistance in S. aureus infections or carriage, resistance proportions and 
prevalence of MRSA infections and carriage can be compared inappropriately. By definition, the 
prevalence of MRSA in a population, usually measured with sample-based approaches, will be 
lower than the resistance proportion among S. aureus isolates (usually measured with isolate-based 
strategies) as the former includes clinical samples that test negative for S. aureus. While prevalence 
and resistance proportions for MRSA infections measured by sample-based and isolate-based 
strategies are useful for surveillance purposes as they indicate the proportion of MRSA isolates 
detected in a specific population and S. aureus isolates respectively, this review indicates that these 
measures may be particularly vulnerable to differences in the demographic and health status of 
populations studied. The interpretability of either sample-based or isolate-based data is largely 
limited by the lack of relevance to patients and their clinical conditions. 
 
Of the 229 studies included in this review, we observed substantial disparities in the demographic 
and health status of populations studied, screening and sampling policies, and study periods, 
similar to what Dulon et al. reported in an earlier review on MRSA prevalence in European 
healthcare settings,34 These factors, along with differences in study settings, AST methods and 
sampling sites, were often suggested as potential sources of heterogeneity in MRSA detection.34-
36 This is consistent with findings from our meta-analysis, where study heterogeneity was found 
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to account for more than 99% of the variance between study estimates of MRSA prevalence and 
resistance proportions. 
 
Of all potential contributors to variability in MRSA carriage, estimates at the population level, 
relatively better-documented ones include age group,37, 38 and sample population groups based on 
health and admission status (i.e. inpatient, outpatient, and healthy people).39 In our study, we found 
MRSA carriage prevalence higher in adults 65 years or older compared with children below the 
age of 18 years. While existing literature on the differences in MRSA carriage among different 
age groups is inconsistent,40 the higher MRSA carriage prevalence in older adults reported in our 
study might be the result that most of the studies were conducted in long-term care facilities or 
nursing homes in the region.41-44 This is in contrast with MRSA carriage studies in children or 
adults, which were often conducted in community settings among healthy participants 45-70. We 
also found MRSA carriage to be lower in outpatients and healthy participants compared with 
inpatients, which is congruent with the increased likelihood of exposure to resistant organisms in 
the hospital setting among inpatients.39  
 
For MRSA infections, we did not find statistically significant differences in prevalence or 
resistance proportions across age groups. Previous studies also suggested an inconsistent pattern 
in MRSA infections among different age groups,71 with some studies reporting a higher prevalence 
of MRSA infections in older adults72 and others showing the prevalence of MRSA infections 
higher in children and young adults.73, 74 Nevertheless, our study suggested that MRSA resistance 
proportions of MRSA infections varied by source of infections. Consistent with previous studies, 
resistance proportions for CA-MRSA seem to be lower than HA-MRSA infections,6 reflecting the 
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higher proportion of MRSA among S. aureus found in healthcare settings compared with 
community settings.  
 
As S. aureus most commonly causes skin or soft tissue, respiratory tract, and bloodstream 
infections.75 Most studies included in this review reported prevalences and resistance proportions 
of MRSA infections in isolates sampled from one or more of these sites. We did not find 
statistically significant differences in prevalences or resistance proportions of MRSA infections in 
blood, respiratory tract, and skin or wound samples. An important caveat to this finding is that we 
did not record and consider the type of infection that is associated with the collection of samples 
for testing (e.g. blood samples collected from patients with respiratory infections are not 
differentiated from those collected from patients with bacteraemia). 
 
Given the highly circumstantial nature of prevalence and resistance proportions measured by 
isolate-based and sample-based approaches, it may be useful to consider moving towards 
surveillance approaches (such as case-based surveillance) in which pathogens and resistance 
patterns identified through laboratory testing can be explicitly related to patients’ clinical 
conditions or diseases, which may provide data of clinical relevance to guide medical practice, and 
at the same time reduce data variability within the sample population. The levels of antibiotic 
resistance measured by isolate-based and sample-based strategies typically contain little 
information about the proportion of MRSA infections within a specific group of infections, such 
as skin infections or lower respiratory tract infections such as pneumonia. Studies using isolate-
based measurement strategies tend to collect subsequent clinical samples for testing within a 
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selected period while sample-based strategies tend to collect samples from groups defined by their 
health or hospitalization status.   
 
In contrast to a recent study by Alvarez-Uria and colleagues that found a negative association 
between GNI per capita and methicillin resistance in S. aureus isolates,76 the prevalence of MRSA 
infections and carriage significantly increased with GNI per capita in our study. However, a 
significant negative association was found between GNI per capita and resistance proportions of 
MRSA infections. As Alvarez-Uria and colleagues included mostly data from European countries 
and only two countries from the Asia Pacific (Thailand and Australia),76 this may suggest that the 
differences in proportions of MRSA infections and carriage by country income status in Asia 
Pacific may be different than of Europe, in that better-resourced countries in Asia may have higher 
methicillin-resistance among S. aureus isolates compared with countries with less resources. 
However, unlike Europe, where countries with higher gross national income (GNI) per capita tend 
to have a lower rate of antibiotic consumption and better AMR surveillance and stewardship, this 
correlation is still unclear in Asia Pacific countries. Generally, better-resourced countries in Asia 
Pacific have more AMR surveillance and stewardship programs in place,16 but differences in 
antibiotic consumption between better and less well-resourced countries may be less apparent in 
the region compared to European countries77. For instance, in a systematic review by Morgan et 
al., better resourced countries in Europe reported less non-prescription use of antimicrobials in the 
general population than less well-resourced countries.77 This is in contrast with countries in Asia, 
where non-prescription use of antimicrobials in China was reported to be 36% compared with 
Indonesia (17%), India (18%), Vietnam (62%), and Bangladesh (86%).77   
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Our review has a few limitations. First, as our review was limited to data published on international 
bibliographic databases, the findings derived from our review may lack the insights of unpublished 
data from health authorities in the Asia Pacific region. However, the reported resistance 
proportions and prevalence of MRSA in the countries included in our study are generally 
comparable with data reported to the Global Antimicrobial Resistance Surveillance System.78 
Secondly, the inclusion of only published literature written in English also excluded data that were 
presented in other languages. Although a formal quality assessment was not conducted on included 
studies, we have incorporated several quality-related exclusion criteria to exclude studies that are 
likely to be of lower quality. These include the lack of information on laboratory methods and 
clearly defined study periods. 
 
In conclusion, the resistance proportions and prevalence of MRSA infections in the Asia Pacific 
is comparable to those reported in other regions. Although there appears to be no significant secular 
changes in prevalence or resistance proportions of MRSA infections and carriage in the Asia 
Pacific, our results highlight the greater influence of country income status and the characteristics 
of the sample population on these measures compared with methodological differences in AST 
and the need to compare and consider MRSA prevalence and resistance proportions separately as 
these are two distinct metrics.  
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FIGURE LEGENDS 
Figure 1. Flow diagram of study selection. 
 
Figure 2. Number of observations reported for MRSA prevalence and resistance proportions 
in selected locations in the Asia Pacific (2000 – 2016). 
AC
CE
PT
ED
 M
AN
US
CR
IPT
29 
 
Figure 3. MRSA prevalence and resistance proportions reported in Asia Pacific by year of 
publication. Panel A. MRSA prevalence, defined as the proportion of MRSA among all tested 
samples, reported in selected countries between year 2000 and 2016. For studies that report 
prevalence for more than one year, the midpoint of the study is reported as the study year. Bubble 
sizes reflect the study sample size for each observation. Panel B. MRSA resistance proportion, 
defined as as the proportion of MRSA among all S. aureus isolates, reported in selected countries 
between year 2000 and 2016. For studies that report prevalence for more than one year, the 
midpoint of the study is reported as the study year. Bubble sizes reflect the study sample size for 
each observation. Panel C. Number of publications that report MRSA prevalence in selected 
countries in year 2000 – 2017. Panel D. Number of publications that report MRSA prevalence in 
selected countries in year 2000 - 2017.  
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Figure 4. MRSA prevalence and resistance proportion by source of infection and population 
segment. Panel A. MRSA prevalence reported in selected countries by source of patients or 
persons sampled. Panel B. MRSA prevalence reported in selected countries by source of infection. 
Panel C. MRSA resistance proportion reported in selected countries by source of patients or 
persons sampled. Panel D. MRSA resistance proportion reported in selected countries by source 
of infection. MRSA prevalences and resistance proportions for studies with unknown source of 
infection or population groups are not included. 
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Table 1. Summary of the studies included in the analysis. 
 Studies, n 
Total number of articles included 229 
Publication year 
2000 – 2006 
2007 – 2011 
2012 – 2017 
 
19 
59 
151 
 Observations, n 
Total number of observations included a 346 
Study setting 
Healthcare 
Community 
Healthcare and community (mixed) 
Animal/livestock-related 
 
311 
25 
4 
6 
Number of study sites 
Single site 
2 – 10  
> 10 or multiple sites 
 
209 
63 
74 
Sample population 
Inpatient 
Outpatient 
Healthy participants 
Mixed 
Not reported 
 
146 
53 
53 
66 
28 
Age group of study participants 
Children (0 – 17 years) 
Adults (18 – 64 years) 
Older adults (65 years and above) 
All ages/not reported 
 
39 
129 
30 
148 
Source of infection 
Hospital-associated 
Community-associated 
Hospital- and community-associated 
Carriage 
Livestock-associated 
 
53 
60 
147 
83 
3 
Measure of antibiotic resistance 
Resistance proportion b 
Prevalence c 
 
293 
216 
Laboratory method 
Agar dilution 
Automated systems 
Broth dilution 
Chromogenic agar 
Disk diffusion 
Etest 
Oxacillin agar test 
PCR and/or molecular typing methods 
 
10 
53 
70 
21 
156 
3 
2 
12 
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Mixed 19 
Antibiotics tested d 
Cefoxitin 
Methicillin 
Oxacillin 
Flucloxacillin 
More than one antibiotic tested 
Not applicable 
 
75 
15 
226 
10 
26 
45 
Sampling site 
Blood only 
Respiratory tract only 
Skin/Wound only 
Mixed sites 
Not reported 
 
47 
75 
24 
175 
25 
a The total number of articles included in this study differs from the total number of studies (observations) included 
because some articles include data for more than one country, year, sample population, or study setting. 
b Resistance proportion is defined as the proportion of methicillin-resistant S. aureus (MRSA) out of the total S. aureus 
isolates subjected to susceptibility testing for methicillin resistance. 
c Prevalence is defined as the proportion of MRSA out of the total number of specimens collected or patients recruited 
in the study. 
d Antibiotics used for susceptibility testing are not recorded for studies that use automated antibiotic susceptibility 
testing (AST) methods or genotyping and screening methods such as resistance gene identification with polymerase 
chain reaction (PCR) and biochemical (chromogenic) MRSA screening tests.  
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Table 2. Reported MRSA prevalence and resistance proportions by country (2000 -2016) 
 
 
Prevalence (%) 
Range (min, max) 
 Resistance proportion (%) 
Range (min, max) 
Country Infections# Carriage 
 
Infections# Carriage 
American Samoa 8.0* -  17.4* - 
Australia 2.2, 26.0 1.21, 16.00  7.25, 82.50 3.10, 50.00 
Cambodia - 3.50, 4.10  - - 
Chi- 0.5, 55.30 0, 10.50  2.62, 98.40 0, 47.83 
Hong Kong 0.22, 28.00 0.52, 39.06  2.00, 84.80 1.12* 
Indonesia - 6.04, 9.33  - 0, 21.43 
Japan 0.70, 41.00 0.78, 30.20  24.35, 72.00 14.81, 88.89 
Korea 0.58, 73.00 0, 36.10  10.59, 81.44 0, 71.92 
Laos 0 -  0, 7.30) - 
Malaysia 1.01, 32.00 0, 2.10  7.90, 60.00 0, 6.67 
Mongolia - -  8.8* - 
Myanmar 0.15, 2.97 -  4.35, 38.73 - 
New Zealand 0.50, 9.00 8.2*  1.54, 2.94 14.6* 
Papua New Guinea 2.6* -  75.0* - 
Philippines 59.0* -  30.10, 80.00 - 
Singapore 4.80, 52.00 1.79, 20.20  70.0* - 
Taiwan 0, 29.00 0.60, 32.20  0, 97.30 5.26, 77.03 
Thailand 0, 53.00 0, 3.60  0, 71.40 0, 6.67 
Vietnam 0, 3.00 7.90, 8.59  0, 90.00 65.5* 
# Infections include hospital-associated (HA), community-associated (CA), mixed (HA and CA), and 
livestock/animal-associated MRSA infections 
* Only one observation recorded 
-: no data available 
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Table 3. Variables potentially associated with the prevalence and resistance proportion of MRSA carriage identified in the meta-regression analysis. 
 Prevalence  Resistance proportion 
 β 95% CI  β 95% CI 
Study year -0.002 -0.011,  0.007  0.007 -0.017,  0.031 
      
Age group a      
Children (0 – 17 years) Referent  Referent 
Adults (18 – 64 years) -0.022 -0.010,  0.056  -0.117 -0.313,  0.079 
Older adults (≥ 65 years) 0.097 0.002,  0.192  0.148 -0.111,  0.407 
All ages/not reported 0.019 -0.073,  0.110  -0.240 -0.527,  0.046 
      
GNI per capita b 0.021 0.003,  0.039  0.014 -0.044,  0.072 
      
Population group      
Inpatients Referent  Referent 
Outpatients -0.112 -0.201, -0.022  -0.151 -0.403,  0.101 
Mixed -0.103 -0.306,  0.099  0.036 -0.465,  0.536 
Healthy participants -0.097 -0.163, -0.030  -0.225 -0.423, -0.027 
      
Model characteristics k=80, I2=98.06%, R2=24.71%  k=51, I2=97.44%, R2=14.74% 
a The median or average of participants included in the study. 
b World Bank data for country gross national income per capita in 2016.79  
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Table 4. Variables potentially associated with the prevalence and resistance proportion of MRSA infection identified in the meta-regression analysis. 
 Prevalence  Resistance proportion 
 β 95% CI  β 95% CI 
Study year 0.008 -0.001, 0.017  0.001 -0.007, 0.009 
      
Age group a      
Children (0 – 17 years) Referent  Referent 
Adults (18 – 64 years) 0.090 -0.018, 0.199  0.038 -0.084, 0.160 
Older adults (≥ 65 years) 0.044 -0.123, 0.211  0.046 -0.132, 0.224 
All ages/not reported 0.108 -0.004, 0.220  0.026 -0.100, 0.152 
      
GNI per capita b 0.022 0.005, 0.039  -0.024 -0.041, -0.007 
      
Source of infection      
Hospital-associated Referent  Referent 
Community-associated -0.011 -0.112, 0.091  -0.315 -0.413, -0.217 
Hospital- or community-associated 0.058 -0.032, 0.148  -0.100 -0.183, -0.017 
Livestock/animal associated -0.128 -0.341, 0.086  -0.417 -0.716, -0.119 
      
Model characteristics k=136, I2=99.84%, R2=10.86%  k=242, I2=99.47%, R2=21.47% 
a The median or average of participants included in the study 
b World Bank data for country gross national income per capita in 201679  
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